Amoroso Michael 4

4 · PRECISION BIOSCIENCES INC · Filed Jan 22, 2025

Form 4

Period: 2025-01-20

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
2025-01-20+115,388→ 143,925 total
Sale
Common Stock
2025-01-21$4.67/sh−36,838$172,033→ 107,087 total
Exercise/Conversion
Restricted Stock Units
2025-01-20−8,888→ 8,888 total
→ Common Stock (8,888 underlying)
Exercise/Conversion
Restricted Stock Units
2025-01-20−37,079→ 74,138 total
→ Common Stock (37,079 underlying)
Exercise/Conversion
Restricted Stock Units
2025-01-20−69,421→ 138,842 total
→ Common Stock (69,421 underlying)

Footnotes (6)

[F1]Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2025.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
[F4]On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
[F5]On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
[F6]On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Documents

1 file